Text Size
18 studies found for:    "Neurofibromatosis type 2"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Neurofibromatosis 2;   Vestibular Schwannoma
Intervention: Drug: Lapatinib
2 Active, not recruiting Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Conditions: Acoustic Schwannoma;   Neurofibromatosis Type 2
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
3 Recruiting Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Conditions: Neurofibromatosis Type 2;   Neuroma, Acoustic
Intervention: Drug: RAD001, everolimus
4 Not yet recruiting Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Progressive Vestibular Schwannomas
Intervention: Drug: Bevacizumab
5 Active, not recruiting Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Condition: Neurofibromatosis 2
Intervention: Drug: RAD001
6 Active, not recruiting Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®
7 Suspended PTC299 for Treatment of Neurofibromatosis Type 2
Condition: Neurofibromatosis 2
Intervention: Drug: PTC299
8 Completed An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
Condition: Neurofibromatosis 2
Intervention: Device: Penetrating auditory brainstem implant
9 Recruiting Concentration and Activity of Lapatinib in Vestibular Schwannomas
Conditions: Vestibular Schwannoma;   NF2;   Neurofibromatosis 2;   Acoustic Neuroma;   Auditory Tumor
Intervention: Drug: lapatinib
10 Recruiting Natural History Study of Patients With Neurofibromatosis Type 2
Conditions: Spinal Cord Disease;   Intracranial Central Nervous System Disorder;   Neurologic Disorders;   Brain Neoplasms
Intervention:
11 Recruiting Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Conditions: Acoustic Schwannoma;   Adult Anaplastic Meningioma;   Adult Ependymoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Meningeal Hemangiopericytoma;   Adult Papillary Meningioma;   Neurofibromatosis Type 1;   Neurofibromatosis Type 2;   Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
12 Unknown † NF2 Natural History Consortium
Conditions: Schwannoma, Vestibular;   Neurofibromatosis 2;   Meningioma
Intervention:
13 Completed Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
Condition: Neurofibromatosis 2
Intervention: Device: Multichannel Auditory Brain Stem Implant
14 Recruiting Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Conditions: Neoplasms;   Nervous System Disease;   Vestibular Disease
Intervention:
15 Completed Analysis of NF2 Mutations in Radiation-Related Neural Tumors
Condition: Neural Tumors
Intervention:
16 Completed Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: everolimus
17 Not yet recruiting Feasibility Study of Auditory Brainstem Implant in Young Children
Conditions: Bilateral Cochlear Aplasia;   Bilateral Cochlear Nerve Deficiency;   Bilateral Cochlear Ossification Secondary to Meningitis
Intervention: Device: Auditory brainstem implant
18 Active, not recruiting Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Conditions: CNS Cancer;   Meningioma;   Intracranial Hemangiopericytoma;   Hemangioblastoma;   Neurofibromatosis
Intervention: Drug: Sunitinib
To Top

† Indicates status has not been verified in more than two years